Interview: Jung Hyun Ho – Founder & CEO, Medytox – Korea
Medytox is the most valuable pharmaceutical business in Korea, with a highly successful botulinum toxin product on the market, and can only grow further when they finish development of their…
Medytox has successfully developed the fourth botulinum toxin type A product in the world, and today exports products to more than 60 countries including Japan, Thailand, India, and Brazil. Medytox has been making efforts to penetrate into the US and European market in the near future to show its presence as a leading global biopharmaceutical company.
Medytox is at the forefront of the Korean biopharmaceutical industry, thanks to its excellent R&D capabilities with top-teir biotechnologists, and to its state-of-the-art operations and production facilties. Moreover, Medytox is going to become a frontier in the field of biopharmaceuticals due to its passion and courage to embrace global challenges.
Contact Details
78, Gangni 1-gil, Ochang-eup, Cheongwon-gu,
Cheongju-si, Chungcheongbuk-do
Korea
Medytox is the most valuable pharmaceutical business in Korea, with a highly successful botulinum toxin product on the market, and can only grow further when they finish development of their…
Dae Jung Kim, president of Daiichi Sankyo Korea provides an insight into the rationale behind the company’s focus on the cardiovascular therapeutic area in South Korea. Mr Kim also reveals…
Kyung Kook Lee, chairman of KMDIA, explains the association’s role in working with the medical devices industry to boost both the local market and to raise Korea’s profile as a…
Jung Hyun Yun lifts the lid on Biosolution’s new stem cell technology that could revolutionize the treatment of cartilage-related ailments, such as osteoarthritis. He also discusses the plans for global…
Antimicrobial resistance (AMR) is a global health concern that we are increasingly understanding the consequences of and pulling together to try and keep under control. Korea is one of the…
Paul Henry Huibers, president of Lilly Korea discusses Lilly’s strong double-digit growth following a challenging period of restructuring. Huibers offers his opinion on the pricing difficulties within the Korean market,…
The South Korean government has designated the promotion of artificial intelligence (AI)-based drug development and healthcare innovation as a national priority. This new policy aims to capitalise on Korea’s advanced…
Uloff Münster, general manager of Merck Biopharma Korea provides his insights into the Korean healthcare system. Dr Münster also discusses the drug pricing situation in Korea and the potential for…
Young Jack Lee, CEO of LSK Global PS, Korea’s largest local contract research organization (CRO) gives his insights on the evolution of the clinical research environment over the past four…
Yong-Ik Kim, president of Korea’s National Health Insurance Service (NHIS), provides an insight into the implementation of the upcoming MoonCare reforms, the government’s strategy to ensure the expansion of coverage…
Kyungjin Peter Kim, CEO of ST Pharm, provides an insight into his expansion of the company’s operations from simply a CMO into a CDMO and new drug development. He also…
Sean Kim, senior director at the Korea Research-Based Pharma Industry Association (KRPIA) gives his assessment of the role of MNCs within the pharma industry in South Korea. At the…
Roger Zbinden, head of the Swiss Business Hub Korea, explains their efforts to raise the profile of the South Korean market for Swiss business. Dr Zbinden also provides his insights…
See our Cookie Privacy Policy Here
